Reported about 16 hours ago
BioMarin Pharmaceutical Inc. has announced the acquisition of Inozyme Pharma for $270 million to enhance its rare disease research efforts. The cash transaction, expected to close between July and September, will give BioMarin control over INZ-701, a promising enzyme replacement therapy for conditions related to ENPP1 and ABCC6 deficiencies. Despite the small patient population, analysts see potential for growth within BioMarin's existing product line, although opinions vary on the overall impact on its market position.
Source: YAHOO